On ****, DiChe Medicine rose more than 10%, and Shanghai Allist Pharmaceuticals Co., Ltd., Kainuo Technology, Junshi Bio, Zai Lab, and Beigene were among the top gainers. Tianfeng Securities pointed out that many Chinese innovative drug companies released their latest results at the American Society of Clinical Oncology (ASCO) annual meeting. Logically speaking, by going abroad to realize commercial value, highly innovative varieties, flexible transaction forms, and the potential to share in the high-paying markets in Europe and America.
A股创新药板块继续走强 迪哲医药涨超10%
The innovative drugs sector of A-shares continued to strengthen, and DiZhe Medicine rose more than 10%.
The translation is provided by third-party software.
The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.